2.4
陽電子放出断層撮影(PET)は、放射性医薬品を用いる医療画像診断技術です。最初のPETスキャナは1961年に導入されましたが、その後15年かかり、放射性医薬品がこの技術と組み合わされ、その可能性が革新されました。
PET 検査の主な要件の1つは陽電子放射性同位元素であり、これはサイクロトロンで生成さ…
陽電子放出断層撮影法(PET)は、腫瘍の検出、転移の程度の判断、血液供給障害などの心臓疾患の評価、脳内の神経活動の研究に一般的に使用される放射性トレーサーベースの医用画像技術です。
PETスキャンを行うために、患者には、炭素11、酸素15、フッ素18などの陽電子放出同位体に結合した生体分子である放射性トレーサーを注射することが最も多いです。
体内に入ると、これらの放射性トレーサーは組織または細胞内に蓄積し、親和性が高くなります。例えば、フルオロデオキシグルコースまたはFDGは、代謝活性が高いため、腫瘍に多く蓄積します。
不安定な放射性フッ素は崩壊し、陽電子(正に帯電した電子の反粒子)を放出します。陽電子は近くの電子と結合して消滅反応を引き起こし、511 keVエネルギーの2つの光子を反対方向に放出します。
PET検出器は、これらの数百万の消滅イベントを収集し、複雑な計算アルゴリズムを使用して、調査対象の領域におけるトレーサー分布の画像を再構築します。
View the full transcript and gain access to JoVE Core videos
Q1: What is positron emission tomography and what are its main clinical applications?
Positron emission tomography (PET) is a radiotracer-based medical imaging technique that detects positron-emitting isotopes to visualize tissue function. PET is widely used to diagnose tumor detection, determine cancer metastases, evaluate heart disease and impaired blood supply, study brain neural activity, and assess infections, bone disease, and thyroid conditions. Unlike static imaging, PET reveals physiologic activity including nutrient metabolism and blood flow.
Q2: How do radiotracers work in a PET scan?
Radiotracers are biological molecules bound to positron-emitting isotopes like fluorine-18 or carbon-11. When injected into the patient, they accumulate in tissues with higher affinity, such as tumors with elevated metabolic activity. For example, fluorodeoxyglucose (FDG) concentrates in cancer cells because they metabolize glucose differently than normal tissue, allowing PET to detect abnormal regions.
Q3: What happens during the positron annihilation process in PET imaging?
Radioactive fluorine decays and emits positrons, which are positively charged antiparticles of electrons. When positrons combine with nearby electrons, an annihilation reaction occurs, emitting two photons of 511 keV energy in opposite directions. PET detectors collect millions of these annihilation events and use complex computing algorithms to reconstruct detailed images of tracer distribution in the body.
Q4: How is a radiotracer prepared for use in PET scanning?
Positron-emitting radioisotopes are produced in a cyclotron through proton bombardment. For example, fluorine-18 is created by bombarding oxygen-18, then incorporated into a glucose analog called fludeoxyglucose (FDG). This tagged compound is then injected intravenously or inhaled as a gas, allowing the scanner to track how tissues utilize the radiotracer.
Q5: How does PET imaging differ from CT and MRI scans?
PET scans reveal physiologic activity, including nutrient metabolism and blood flow, showing how organs function. In contrast, computed tomography and magnetic resonance imaging produce static anatomical images. PET is now typically performed alongside computed tomography or magnetic resonance imaging to provide comprehensive data visualization and improve diagnostic interpretation.
Q6: What information can PET imaging reveal about brain function?
PET can locate regions in the brain that become active during specific activities such as speaking or closing the eyes. By tracking radiotracer accumulation in different brain areas, PET reveals neural activity patterns and can detect brain abnormalities. This functional imaging capability makes PET valuable for studying cognitive processes and diagnosing neurological conditions.
Q7: What are the advantages of using different radiotracers in PET imaging?
Different radiotracers target specific tissues based on their biological properties. For example, radioactive iodine monitors thyroid function, while radioactive gallium detects cancer. Fluorodeoxyglucose (FDG) reveals glucose metabolism differences between normal and abnormal tissues. This versatility allows PET to diagnose diverse conditions by selecting radiotracers that accumulate in the target organ or pathology.